FDA ta amince da Qelbree, wani sabon magani na ADHD wanda ba shi da kuzari

News Wannan shine sabon zaɓi na farko wanda ba'a yarda dashi ba wanda aka amince dashi ga yara cikin shekaru 10

Hukumar Abinci da Magunguna ta Amurka (FDA) ta amince da Qelbree, sabon magani na farko wanda ba na kara kuzari ba ga maganin rashin kulawar cututtukan hankali (ADHD) a cikin yara da matasa a cikin shekaru fiye da 10.

Irƙira ta Supernus Pharmaceuticals, Inc., Qelbree (viloxazine Extended-release capsules) shine mai zaɓin maganin norepinephrine reuptake - rukunin magunguna da ake yawan amfani dasu don magance damuwa da damuwa, kuma wani lokacin ADHD. Qelbree an yarda dashi don yiwa matasa masu cutar ADHD tsakanin shekaru 6 zuwa 17 shekaru.

Qelbree: Wani sabon zaɓi na ba da magani na ADHD

Kimanin 70% na yaran da ke tare da ADHD suna shan wasu nau'ikan magunguna don shi, a cewar Cibiyar Kula da Lafiya ta Hauka ta ƙasa (NIMH).

Yawancinsu ana ba su magunguna masu kara kuzari, wanda ke aiki don haɓaka matakan dopamine a cikin kwakwalwa don taimaka musu su mai da hankalinsu sosai. Koyaya, wasu iyayen sun gwammace su guji sanyawa theira childrenansu stima outa saboda damuwa da illoli kamar rashin nutsuwa, matsalolin bacci, rashin cin abinci, da sauransu. Ko kuma, wasu yaran ba za su iya shan abubuwan kara kuzari ba saboda wani yanayin kiwon lafiya.

Amincewar Qelbree na nufin cewa da sannu iyaye za su sami wani zaɓi don kula da 'ya'yansu tare da ADHD.

A halin yanzu, akwai wasu magungunan ADHD guda uku wadanda basu da kuzari Hakanan yana da yardar FDA: Strattera ( atomoxetine ), Intuniv da Tenex ( guanfacine ), da Kapvay ( clonidine ER ).

Ina ganin yana da matukar mahimmanci a sami wani zaɓi mara motsawa, in ji shi Andrew Cutler, MD , farfesa a likitan kwantar da hankali a SUNY Upstate Medical University da kuma mai binciken gwaji na asibiti wanda yayi nazarin amfani da Qelbree. Wannan yana ɗaya daga cikin manyan buƙatu waɗanda ba a bayyana su a cikin maganin ADHD.

Ina matukar farinciki game da irin karfin da yake da shi, in ji likitan hauka Sasha Hamdani , MD, Kwararren likita na ADHD a Kansas City. Ina son gaskiyar cewa ba mai tayar da hankali bane, don haka rage yuwuwar cin zarafi da sanya shi ƙasa da ƙarancin ƙarfi don samu.

Amfanin Qelbree

Tare da sabon zaɓin magani na ADHD, ya sami sabbin fa'idodi ga yara masu ADHD.

1. Sabon magani

Ba kamar sauran magungunan ADHD ba, ba a samun Qelbree a cikin tsari mai kyau, bayanin kula Dr. Cutler. (Strattera da tsarinta, atomoxetine, sun zo a cikin kwantena, amma dole ne a ɗauke su gabadaya.) Wannan yana nufin iyaye na iya fasa buɗe kawunansu kuma su yayyafa abin da ke cikin ƙwanƙun Qelbree a cikin karamin cokalin applesauce. Akwai wasu marasa lafiya da ba za su iya haɗiye kwaya ba – ko ba za su yi ba, Dr. Cutler ya ce. Wannan yana ba da wani zaɓi don shigar da magani a cikinsu.

2. Saurin fara

Wata fa'ida, a cewar Dokta Cutler, ita ce farkon farawa cikin sauri don inganci. Wato, maganin baya daukar tsawon lokaci don fara aiki da taimakawa yaron da yake buƙatarsa.

3. endedirƙira-sakin tsari

Dokta Hamdani ya ce, gwamnatin da ake yi sau daya a kowace rana kyauta ce. Yana sauƙaƙa buƙatar gano jaka a cikin yini, wanda zai iya zama mai wahala da rashin gaskiya, musamman idan iyaye suna da ADHD.

Rashin dacewar Qelbree

Akwai wasu iyakoki ga sabon magani.

1. Gargadin magunguna

Kamar yadda yake tare da atomoxetine, lakabin Qelbree yana dauke da gargaɗi game da tunanin kashe kai da halaye a cikin marasa lafiyar yara. Dole ne marasa lafiya na kowane zamani da aka bi da waɗannan magunguna su sanya ido sosai.

2. Iyakantaccen amfani

A halin yanzu, yarda ga Qelbree kawai don amfani ga yara da matasa. Amma bincike yana gudana don bincika iyawar sa tare da manya da ADHD , ma. Kamar yadda Dokta Cutler ya lura, ADHD yanayi ne na rayuwa wanda ke shafar manya, yawancin su kuma suna shan magani. Dangane da NIMH, yaɗuwar ADHD a cikin manya a Amurka shine game da 4.4% , tare da abubuwan da ke faruwa sau da yawa a cikin maza fiye da na mata.

Supernus na shirin samarda Qelbree ga marasa lafiya a ƙarshen kwata na biyu na 2021, wanda ke nufin zai iya kasancewa cikin shiri don farkon sabuwar shekarar karatu .